In 2012, there were roughly 41,000 overdose deaths in the United States. Last year, the number topped 100,000. In 2012, there were 4.7 murders for every 100,000 people. Last year, the rate hit an estimated 6.9, a 47 percent increase. A decade ago, you rarely heard of carjackings. Now, they are through the roof. Shoplifting? Ditto. The nation’s mental health was in steep decline before the pandemic, with a 60 percent increase of major depressive episodes among adolescents between 2007 and 2019. Everything we know about the effects of lockdowns and school closures suggests it’s gotten much worse.
Category: COVID-19 and Public Health
Monday Links
Doctors file lawsuit against HHS over paying more to docs who practice “woke” medicine.
Why don’t medicines have names that are easy to pronounce and remember?
Biden Adm. wants certificate of need for charter schools.
There aren’t enough Covid boosters for everyone to have a second booster by Sept 1.
Sec. Mark Esper: Trump proposed shooting Patriot missiles into Mexico to destroy drug labs.
What if Future Voters Could Vote?
An interview with Alex Tabarrok:
Future residents don’t have the vote, so we prevent building which placates the fears of current homeowners but prevents future residents from moving in. Future patients don’t have the vote, so we regulate drug prices at the expense of future new drug innovations and so forth. This has always been true, of course, but culture can be a solution to otherwise tough-to-solve incentive problems. America’s forward looking, pro-innovation, pro-science culture meant that in the past we were more likely to protect the future.
Drug Maker’s Copay Assistance Ended Up in Drug Plans’ Pockets
A while back I wrote about drug company copay assistance programs. The purpose of these is to entice patients to use higher-cost brand drugs by blunting health plan incentives for enrollees to choose lower-cost drug options.